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1108Objectives: Nebulization is a potential method for delivering therapeutic agents to lung grafts. Recent evidence
suggests that nitrite may mitigate ischemia–reperfusion injury via a nitric oxide–dependent pathway.
Methods: Syngeneic orthotopic left lung transplantation was performed in rats after 7 hours of cold ischemia.
Sodium nitrite (3 mg) or phosphate-buffered saline (controls) was delivered before procurement via
nebulization.
Results: Nitrite treatment was associated with better oxygenation, lower peak airway pressure, lower wet/dry
ratio, reduced myeloperoxidase level and macrophage infiltration, increased cyclic guanosine monophosphate
(cGMP) levels, and decreased levels of interleukin 6, interleukin 1-b, inducible nitric oxide synthase, and
intercellular adhesion molecule-1 at 2 hours after reperfusion. Treatment with 2-(4-carboxypheny)-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide, a nitric oxide scavenger, reversed the beneficial effects of nitrite
and decreased cGMP concentration in grafts. A dose-response curve of nitrite was performed at the following
doses: 0.3 mg (N0.1), 3.0 mg (N1.0), 5.25 mg (N1.75), 7.5 mg (N2.5), and 15.0 mg (N5.0). All treatments, ex-
cluding N1.0, resulted in poorer oxygenation, higher peak airway pressures, and higher wet/dry ratio. Higher
dosage groups (N1.75, N2.5, and N5.0) exhibited positive immunostaining of nitrotyrosine and increased the
intensity of nitrotyrosine in immunoblotting.
Conclusions: These data suggest that nebulized nitrite limits lung ischemia–reperfusion injury and may prove
a clinically useful strategy but requires appropriate dosing to limit oxidative injury at high doses. (J Thorac Car-
diovasc Surg 2013;145:1108-16)Supplemental material is available online.
The lung is particularly susceptible to ischemia–reperfusion
injury (IRI), which is in part why lung transplantation (LTx)
remains clinically challenging. Severe IRI occurs in up to
25% of LTx recipients, leading to severe acute graft
dysfunction and significantly increasing the 30-day mortal-
ity risk.1 IRI also causes enhanced cellular and humoral
immune responses against the graft, elevating the risk of
both acute and chronic rejection and resulting in diminished
long-term recipient survival.2 The pathophysiologic events
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The Journal of Thoracic and Cardiovascular Surinflammatory response, enhanced vascular thrombosis, and
apoptosis.3 Diminishing these events could have significant
beneficial effects, improving the outcome of LTx recipients.
Moreover, effective strategies to reduce lung IRI could
potentially expand the use of marginal donor organs, which
are particularly susceptible to IRI, as well as facilitate fur-
ther expansion of the donor pool to donation after cardiac
death (DCD) lungs, which are subject to an obligate period
of warm ischemia.
Nitric oxide (NO) has been demonstrated to mitigate IRI
in many models and is a potential therapeutic agent for pre-
venting lung IRI. However, some studies examining the in-
halational delivery of NO in experimental and clinical
LTx have shown benefit,4,5 whereas others have shown
detrimental or neutral effects.6 These studies suggest that
NO can be either protective or toxic to lung grafts depend-
ing on dose, timing, and duration of exposure and that there
is a narrow therapeutic window for NO.7 Previously, nitrite
was considered a stable product of NO metabolism in vivo.
However, evidence now suggests that nitrite is an important
reservoir of NO and that the reduction of nitrite to NO and
other NO-containingmolecules results in vasodilatation and
blood flow regulation, especially under acidotic and hyp-
oxic conditions.8 Several studies have also recently shown
that nitrite possesses potent cytoprotective properties, in-
cluding reduced apoptosis and cytotoxicity, in the settinggery c April 2013
Abbreviations and Acronyms
cGMP ¼ cyclic guanosine monophosphate
C-PTIO ¼ 2-(4-carboxypheny)-4,4,5,5-
tetramethylimidazoline-1-oxyl-3-oxide
DCD ¼ donation after cardiac death
ELISA ¼ enzyme-linked immunosorbent assay
IL ¼ interleukin
IRI ¼ ischemia–reperfusion injury
LTx ¼ lung transplantation
MPO ¼ myeloperoxidase
NO ¼ nitric oxide
PBS ¼ phosphate-buffered saline solution
PAWP ¼ peak airway pressure
PO2 ¼ oxygen tension
RT-PCR ¼ reverse-transcriptase polymerase chain
reaction
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nitrite contributes to hypoxic vasodilation in the lung and
that nitrite inhibits hypoxic and inflammation-associated
pulmonary arterial hypertension.11,12 Although the
mechanism of its cytoprotective effects against IRI remain
unclear, multiple studies support the idea that nitrite is
reduced to NO with subsequent cytoprotection via
mechanisms paralleling those hypothesized for NO-
mediated cytoprotection.7,13
We have previously demonstrated that nitrite can signif-
icantly inhibit IRI via an NO-dependent pathway when
administered intravenously before the onset of cold ische-
mia.14 Translation of IRI therapeutic strategies to the clinic
in transplantation have been hampered by delivery systems
that require systemic administration in the setting of amulti-
organ donor. Because the lung is unique in that therapeutic
agents can be delivered via inhalation, we aimed to evaluate
and optimize a clinically applicable strategy using nebu-
lized nitrite to mitigate lung IRI. An inhalational delivery
strategy could also potentially be applied in the setting of
DCD donors or in the setting of ex vivo perfusion.E
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SMATERIAL AND METHODS
Animals
The study protocol was approved by the Cleveland Clinic’s Institutional
Animal Care and Use Committee and all animals received humane care in
compliance with the ‘‘Guide for the Humane Care and Use of Laboratory
Animals’’ (Institute of Laboratory Animal Resources, National Research
Council, National Academy Press, Washington, DC, 1996). Specific
pathogen-free inbred male LEW (RT1l) rats (Harlan Sprague Dawley
Inc, Indianapolis, Ind) weighing 290 to 350 g were used.
Orthotopic Left LTx in Rats
Syngeneic orthotopic left LTx was performed using a cuff technique as
previously described.15 In brief, donors received 250 mL of phosphate-The Journal of Thoracic and Carbuffered saline solution (PBS) or 3.0 mg of sodium nitrite (Sigma-Aldrich,
St Louis, Mo) in 250 mL of PBS via nebulization using the MicroSprayer
model IA-1C (Penn-Century Inc, Philadelphia, Pa) after induction of anes-
thesia. Donor rats then underwent tracheotomy and mechanical ventilation
at a positive end-expiratory pressure of 2.0 cm with a mixture of 21% ox-
ygen and isoflurane (Hospira Inc, Lake Forest, Ill). The lungs were flushed
through the main pulmonary artery with 20 mL of 4C Perfadex (Vitrolife,
G€oteborg, Sweden) 30 minutes after nebulization and excised. Grafts were
implanted after 7 hours of cold storage at 4C in Perfadex. Recipient rats
were then extubated and given postoperative care.
Experimental Groups
Rats were randomly allocated into 3 groups: sham, control, and nitrite
(n¼ 7 in each). In the sham group, lungs were harvested under anesthesia,
frozen in liquid nitrogen, and stored at80C. In the control group, after
PBS nebulization during harvest, the left lungs were preserved for 7 hours
at 4C and transplanted. In the nitrite group, after nebulization with 3.0 mg
of sodium nitrite dissolved in 250 mL of PBS, the left lungs were preserved
for 7 hours at 4C and transplanted.
Nebulized Nitrite Dose Response
After initial experiments with nebulization of 3.0 mg of sodium nitrite
(N1.0), a dose response was performed. LTx were performed with the fol-
lowing doses of sodium nitrite: 0.3 mg (N0.1, which means that 0.1 of the
standard dose was given), 5.25 mg (N1.75), 7.5 mg (N2.5), and 15.0 mg
(N5.0) (n ¼ 5 in each group).
Assessing the Effect of 2-(4-Carboxypheny)-4,4,5,5-
Tetramethylimidazoline-1-Oxyl-3-Oxide (C-PTIO),
an NO Scavenger
Two additional groups were administered 3.1 mg/kg intravenously of
C-PTIO (ENZO Life Sciences, Plymouth Meeting, Pa), an NO scavenger,
at different time points after nebulization of 3.0 mg of sodium nitrite to do-
nors. In the C-PTIO 1 group (n ¼ 5), C-PTIO was given to the donors 10
minutes before cold ischemia during harvest, whereas in the C-PTIO 2
group (n¼ 5), C-PTIO was intravenously injected in the recipients 10 min-
utes before reperfusion.
Postoperative Physiologic Evaluation and Tissue
Preparation
Following 2 hours of reperfusion after transplantation, graft pulmonary
vein oxygen tension (PO2) was evaluated (i-STAT, Abbott Point of Care,
East Windsor, NJ) after a recruitment maneuver under anesthesia (inspired
oxygen fraction¼ 1.0). The blood sample of graft pulmonary vein was ob-
tained exactly from the pulmonary vein cuff using a 25-gauge needle under
microscope guidance. The peak airway pressure (PAWP) of the trachea was
recorded. Blood was obtained and immediately centrifuged at 7000 rpm for
6 minutes and the plasmawas frozen in liquid nitrogen and stored at80C.
Graft tissue was retrieved after flushing of the pulmonary artery with PBS,
frozen in liquid nitrogen, stored at 80C, and used for reverse-
transcriptase polymerase chain reaction (RT-PCR), enzyme-linked immu-
nosorbent assay (ELISA), and Western blotting analysis.
Methemoglobin Levels and Nitrite Concentrations
Blood samples were obtained from the abdominal aorta 30 minutes
after sodium nitrite nebulization in the donor, and methemoglobin
levels were immediately measured using an ABL 725 (Radiometer Ag, Co-
penhagen, Denmark). The right lung was flushed by air-equilibrated
PBS supplemented with N-ethylmaleimide/ethylenediaminetetraacetic
acid (10/2.5 mmol/L) (NEM; Sigma-Aldrich) in the donor 30 minutes after
nebulization and stored at80C. After lung tissue was homogenized, ni-
trite concentration in tissue lysates was measured using NOA 280i (GE,diovascular Surgery c Volume 145, Number 4 1109
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SBoulder, Colo). The plasma nitrite concentration was also measured using
the same machine.
Wet/Dry Ratio
The wet weight of frozen lung samples was measured and lungs were
then dried in an oven at 60C for 1 day to obtain the dry weight.
Real-Time RT-PCR
RNAwas extracted from frozen lung tissue by using TRIzol (Invitrogen,
Carlsbad, Calif). The mRNA for interleukin (IL) 6, IL-1b, tumor necrosis
factor-alpha, inducible NO synthase, IL-10, intercellular adhesion
molecule-1, and glyceraldehyde 3-phosphate dehydrogenase were quanti-
fied with iQ SYBR Green Supermix (BIO-RAD, Hercules, Calif), as pre-
viously reported.16 The expression of each gene was normalized with
glyceraldehyde 3-phosphate dehydrogenase.
Myeloperoxidase Activity
Myeloperoxidase (MPO) concentration was evaluated using the Rat
MPO ELISA kit (HyCult Biotechnology, Uden, The Netherlands).
Cyclic Guanosine Monophosphate Measurement
Cyclic guanosine monophosphate (cGMP) was analyzed in lung tissue
with the Cyclic GMP EIA kit (Cayman Chemical Company, Ann Arbor,
Mich). Results were expressed in picomoles (pmol) of cGMP per milligram
of protein.
Histopathologic Analysis
Formalin-fixed, paraffin-embedded graft tissue was sectioned at 5 mm.
Sections were incubated with monoclonal mouse anti-rat ED1 antibody
(Serotec, Raleigh, NC) and anti-nitrotyrosine antibody (Millipore, Teme-
cula, Calif) followed by LSAB horseradish peroxidase detection (DAKO,
Carpenteria, Calif). For ED1 evaluation, the ratio of positive staining to
negative staining was calculated.
Western Blot Analysis
Tissues were homogenized in lysis buffer, electrophoresed on NuPAGE
4%–12% Bis-Tris gel (Invitrogen), and transferred to nitrocellulose mem-
branes (Invitrogen). Membranes were washed and then incubated with
mouse antibodies for nitrotyrosine (Millipore, Temecula, Calif) and rabbit
polyclonal actin (Sigma-Aldrich) followed by incubation with secondary
antibody for 2 hours. Membranes were detected using Immobilon Western
HRP Substrate Peroxide Solution (Millipore, Billerica, Mass) and the Ko-
dak 4000R Image Station (Kodak, Rochester, NY).
Statistical Analysis
All values are expressed as mean  standard error of the mean. Data
were evaluated by analysis of variance or the Student t test. Post hoc test
for the analysis of variance included the Bonferroni multiple comparison
test. All analyses were performed on SigmaStat software version 3.5 (Sy-
stat Software Inc, Richmond, Calif). A value of P<.05 was used to distin-
guish the differences by chance.
RESULTS
Nebulized Nitrite Improved Lung Graft Function
The nitrite group (3.0mg sodium nitrite nebulization) had
higher PO2 levels than the control group (PBS nebulization)
(560.8  29.0 vs 164.0  38.2 mm Hg; P<.001; inspired
oxygen fraction ¼ 1.0). The level of PO2 in the nitrite group
was equivalent to that in the sham group (612.5  15.5 mm
Hg). The nitrite group had lower PAWP than the control1110 The Journal of Thoracic and Cardiovascular Surgroup (5.8 0.3 vs 7.1 0.4mmHg;P¼ .04) and the nitrite
group also had a lower wet/dry ratio than the control group
(7.23  0.58 vs 8.05  0.34; P ¼ .66) (Figure 1, A).
Dose-Dependent Cytoprotective Effects of Nebulized
Nitrite in Lung IRI
To determine the optimal dosage of nebulized nitrite, we
assessed lung graft physiologic function after 2 hours of re-
perfusion at various dosages of nitrite. In the N0.1 group
(0.3 mg sodium nitrite), PO2 was reduced compared with
that in the N1.0 group (3.0 mg) (P<.001). In the higher dos-
age groups (5.25 mg, 7.5 mg, and 15.0 mg), PO2 levels were
lower than that in the N1.0 group (P<.01). Both lower dos-
age (N0.1) and higher dosage groups (N1.75, N2.5, and
N5.0) had higher PAWP levels than the N1.0 group. The
wet/dry ratio in the N1.0 group was lower than those in
the higher dosage groups (Figure 1, B).
Methemoglobin Levels in the Blood, Lung Tissue
Nitrite Concentration, and Plasma Nitrite
Concentration 30 Minutes After Nebulization in
Donor Animals
There was a dose-dependent increase in methemoglobin
levels. The methemoglobin level for the N5.0 group was
above the upper limit level of 37% (Figure 2, A). The nitrite
level in the tissue and the plasma also increased in a dose-
dependent manner (Figure 2, B and C). The N1.0 group
had 6.2%  0.2% methemoglobin, 80.0  10.5 pmol/mg
of tissue nitrite, and 199.3  23.2 mmol/L of plasma nitrite
after nebulization.
Lung Tissue and PlasmaNitrite Concentrations After
2 Hours of Reperfusion in Recipient Animals
To obtain a pharmacokinetic profile for nebulized nitrite,
we measured the plasma nitrite concentration 2 hours after
reperfusion in the control and various dosage groups. The
plasma nitrite mean concentrations of all groups were
within the natural range of 0.1 mmol/L to 0.8 mmol/L
(Figure 2, D).17 The tissue nitrite concentration in the
N1.0 group after 2 hours of reperfusion was reduced to
1.3  0.5 pmol/mg, which was similar to that in the sham
group 30 minutes after nebulization (0.9  0.0 pmol/mg)
(Figure 2, B).
Excessive Formation of Peroxynitrite in Higher
Dosage Groups
To evaluate peroxynitrite formation as a marker of
sodium nitrite toxicity, we performed immunostaining
with anti-3-nitrotyrosine in the graft lungs. In the N1.0
and N0.1 groups, no immunostaining for nitrotyrosine
was observed. In the higher dosage groups (N1.75, N2.5,
and N5.0), epithelial and smooth muscle cells were positive
in all bronchi and bronchioles and all smooth muscle
cells within the vessel walls were positive (Figure 3, A).gery c April 2013
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FIGURE 1. Lung graft physiologic function in experimental groups. A, Pulmonary vein oxygen tension (Po2), peak airway pressure (PAWP) of the trachea,
and graft wet/dry ratio after 2 hours of reperfusion (inspired oxygen fraction¼ 1.0) in sham, control, and nitrite groups. The nitrite nebulization group (nitrite,
n ¼ 7) had higher PO2 levels than the phosphate-buffered saline (PBS) nebulization group (control, n ¼ 7) (560.8  29.0 mm Hg vs 164.0  38.2 mm Hg;
*P<.001). The nitrite group had lower PAWP than the control group (5.8 0.3 mmHg vs 7.1 0.4 mmHg; **P¼ .04). The graft wet/dry ratio in the nitrite
groupwas lower than that in thecontrol group (7.230.58vs8.050.34;P¼ .66).B,Lunggraft physiologic function invarious dosagegroups (0.3mgsodium
nitrite inN0.1, 5.25mg inN1.75, 7.5mg inN2.5, and15.0mg inN5.0; n¼ 5 each) in addition to the standard nitritegroup (N1.0, 3.0mg). In theN0.1 group, PO2
was reduced comparedwith that in thenitrite group (N1.0) (103.6 18.4mmHgvs 560.8 29.0mmHg; *P<.001). In higher dosagegroups (N1.75,N2.5, and
N5.0), PO2 levelswere lower than those in thenitritegroup (N1.0) (289.8 104.1mmHg, 90.4 20.5mmHg, 127.0 49.1mmHg; **P<.01). TheN0.1 group
had higher levels of PAWP than the nitrite group (N1.0) (7.2 0.4mmHg vs 5.8 0.3 mmHg). All higher dosage groups (N1.75, N2.5, and N5.0) had higher
levels ofPAWPthan thenitritegroup (7.30.2mmHg, 7.3 0.4mmHg, and7.6 0.6mmHg, respectively;P¼ .08). Thegraftwet/dry ratio in theN1.0group
was lower than those in higher dosage groups (N1.75, N2.5, and N5.0). PV, Pulmonary vein; IR, ischemia reperfusion.
Okamoto et al Evolving Technology/Basic ScienceMoreover, we performed Western blotting to quantify
nitrotyrosine protein adducts in the graft lungs after
2 hours of reperfusion in various dosage groups. Consistent
with our immunostaining results, there were marked in-
creases in nitrotyrosine immunoreactivity in the higher
dosage groups compared with those in the N0.1 and N1.0
groups. The main nitrotyrosine band intensity compared
with that of b-actin was increased in the higher dosage
groups relative to that in the N0.1 and N1.0 groups
(Figure 3, B and C).E
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SCytoprotective Effects of Optimal Dose of Nebulized
Nitrite via Inhibition of Proinflammatory Mediators,
MPO Activity, and Macrophage Infiltration
In lung grafts exposed to 3.0 mg of inhaled sodium ni-
trite, the expression of IL-6, IL-1b, inducible NO synthase,
and intercellular adhesion molecule-1 in RT-PCR analysis
were lower than that in the control group (P< .05). TheThe Journal of Thoracic and CarIL-10 level in the nitrite group was lower than that in the
control group (P¼ .08) (Figure 4, A). Lung neutrophil infil-
tration is a hallmark of lung IRI. Using ELISA, we mea-
sured MPO activity in the graft, as a marker of neutrophil
sequestration. The nitrite group had lower levels of MPO
activity than the control group (17.6  2.4 vs 31.4  4.9
ng/mL; P¼ .02) (Figure 4, B). Immunohistochemical stain-
ing for activated macrophages (ED1þ) revealed that nitrite
nebulization reduced the ratio of ED1-positive cells
(9.7%  0.3% vs 18.3%  1.0%; P<.001) (Figure 4, C).Elevation of cGMP Levels in the Graft Lung Induced
by Nebulized Nitrite
In other models of ischemic injury, evidence suggests that
the cytoprotective effect of nitrite is mediated by conversion
of nitrite to NO in ischemic tissue beds.18 Inasmuch as there
is considerable evidence demonstrating that the primary
signaling pathway for NO is through activation of solublediovascular Surgery c Volume 145, Number 4 1111
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FIGURE 2. Methemoglobin levels and nitrite concentrations in lung tissue and plasma. A, The methemoglobin level of the nitrite group (N1.0) was 6.2%
 0.2% in donor rats 30minutes after nebulization. Themethemoglobin level increased in a dose-dependent manner. (1.1% 0.0% in sham, 1.3% 0.0%
in N0.1, 11.7%  1.1% in N1.75, and 15.6%  1.5% in N2.5). Data for the N5.0 group were above the upper limit level of 37%. B, The tissue nitrite
concentration in the N1.0 group was 80.0  10.5 pmol/mg in donor lungs 30 minutes after nebulization, while that in N0.1 was 6.6  1.9 pmol/mg. There
was a dose-dependent increase in the lung tissue nitrite concentration in donor lungs at all dosages. The tissue nitrite concentration of recipient lungs in the
N1.0 group was 1.3  0.5 pmol/mg after 2 hours of reperfusion. C, The plasma nitrite concentration was measured in grafts 30 minutes after nebulization.
The nitrite level of N0.1 and N1.0 was 10.0  0.6 mmol/L and 199.3  23.2 mmol/L, respectively. D, The plasma nitrite concentration was measured in
recipient rats after 2 hours of reperfusion. The plasma nitrite concentration in the N1.0 group was 0.34 0.04 mmol/L. The means in all groups were within
the normal physiologic range of 0.1 to 0.8 mmol/L.
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Sguanylyl cyclase resulting in the formation of cGMP, we
measured cGMP levels in lung graft tissue 2 hours after re-
perfusion. There was an increase in the cGMP concentra-
tion in the nitrite group compared with that in the control
group (P¼ .04). The N1.75, N2.5, and N5.0 groups demon-
strated even higher cGMP concentrations than the nitrite
(N1.0) group (Figure 5).
Reversal of the Cytoprotective Effects of C-PTIO by
Nitrite
To further investigate the mechanism of the cytoprotec-
tive effect of nitrite in our model, we examined whether
the tissue protective effect of nebulized nitrite (3.0 mg)1112 The Journal of Thoracic and Cardiovascular Surwould be inhibited by C-PTIO, an NO scavenger. Our group
has previously shown that C-PTIO treatment in donor rats
induces no decline in oxygenation.14 In the CPTIO1 group,
where C-PTIO was administered in donor animals before
cold ischemia, there was a decrease in PO2 compared with
that in the nitrite group (80.2  20.3 vs 560.8  26.8 mm
Hg; P<.001). In the CPTIO2 group, where C-PTIO was ad-
ministered to recipient animals 10 minutes before reperfu-
sion, there was also a decrease in PO2 compared with that
in the nitrite group (70.8  12.4 vs 560.8  26.8 mm Hg;
P<.001) (Figure E1, A). The CPTIO1 and CPTIO2 groups
had higher values of PAWP (P<.01, each) and higher wet/
dry ratios than the nitrite group (Figure E1, B and C). Thegery c April 2013
FIGURE 3. Nitrotyrosine immunostaining and Western blotting. A, In the N0.1 and N1.0 groups, nitrotyrosine staining was negative (b-c: hematoxylin,
340; h-i: hematoxylin,3200). In higher dosage groups (N1.75, N2.5, and N5.0), all bronchiole epithelial and smooth muscle cells were positively stained
(d-f: hematoxylin, 340; j-l: hematoxylin, 3200; k: hematoxylin, 3400). In the control group, bronchial epithelial and smooth muscle cells were slightly
positive (a: hematoxylin,340; g: hematoxylin,3200).Arrows indicate positively stained epithelial cells (black) and smoothmuscle cells (gray). B,Western
blot analysis of nitrotyrosine in the tissue lysates of graft lungs after 2 hours of reperfusion in various dosage groups revealed marked increases in nitration in
the higher dosage groups (N1.75, N2.5, and N5.0) relative to the levels in the N0.1 and N1.0 groups. C, Densitometric analysis revealed that the total nitro-
tyrosine band intensity compared with b-actin was increased in the higher dosage groups (N1.75, N2.5, and N5.0) relative to the levels in the N0.1 and N1.0
groups (N1.0 vs N5.0; *P ¼ .009).
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SCPTIO1 and CPTIO2 groups had lower levels of cGMP
than the nitrite group (Figure 5).
DISCUSSION
Previously, we have demonstrated that nitrite mitigates
lung IRI via an NO-dependent pathway when delivered in-
travenously before the onset of cold ischemia in a lung
transplant model.14 This work is consistent with other stud-
ies demonstrating that intravenous nitrite is cytoprotective
in animal models of heart, liver, kidney, and brain
IRI.10,19,20 In the present study, we demonstrate that
delivery of nitrite to lung grafts via inhalation before the
onset of ischemia mitigates IRI in a dose-dependent fashion
and further demonstrate that high doses of inhaled nitrite are
associated with toxicity and are less efficacious. Nebuliza-
tion is theoretically an ideal method of delivery of therapeu-
tic agents to the lungs. Whereas delivery of nitrite to lungsThe Journal of Thoracic and Carvia nebulization has been reported in models of pulmonary
hypertension and vascular injury,11-13 there have been no
previously reported studies evaluating the efficacy of
inhaled nitrite in the setting of LTx. The therapeutic
efficacy observed as well as the findings of a dose-
dependent increase in donor plasma and lung tissue nitrite
concentration as well as the notable increase in methemo-
globin level in donor blood suggests that nebulization is
an efficient method of drug delivery to lung grafts. Inas-
much as IRI therapeutics in transplantation have been ham-
pered by the need for systemic administration of agents to
donors, the current findings may advance the potential for
clinical translation.
An important finding in our study was that nebulized ni-
trite exhibited dose-dependent cytoprotective effects on
lung IRI as well as dose-dependent toxicity. The standard
nitrite group (N1.0) inhibited lung IRI, whereas both lowerdiovascular Surgery c Volume 145, Number 4 1113
FIGURE 4. Proinflammatory mediators, myeloperoxidase activity, and macrophage infiltration. A, Reverse-transcriptase polymerase chain reaction (RT-
PCR) analysis of proinflammatory cytokines in rat graft lungs after 2 hours of reperfusion. RT-PCR analysis showed that the expression levels of interleukin
(IL) 6, IL-1b, inducible nitric oxide synthase (iNOS), and intercellular adhesion molecule-1 (ICAM-1) were lower in the nitrite group than in the control
group (*P<.05, Student t test). The IL-10 level in the nitrite group was lower than that in the control group (P¼ .08). There was no difference in the tumor
necrosis factor-alpha (TNFa) levels between the nitrite group and the control group (P ¼ .44). B, Myeloperoxidase activity in graft lung. The nitrite group
exhibited lower levels of myeloperoxidase than the control group (17.6 2.4 ng/mL vs 31.4 4.9 ng/mL; *P¼ .02). C, Immunohistochemical staining of
ED1was observed in alveolar pneumocytes. The nitrite group had lower levels of ED1-positive cell than the control group (9.7% 0.3% vs 18.3% 1.0%;
*P<.001).
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did not produce a protective effect on lung IRI. Toxicity
was demonstrated by immunostaining and Western blotting
analyses, which revealed increased levels of nitrated pro-
teins only in the higher dosage groups (N1.75, N2.5, and
N5.0). This dose-dependent toxicity is congruent with re-
ports on the toxic effects of excessive NO or nitrite levels,
which lead to the intracellular generation of ‘‘reactive nitro-
gen species’’ such as peroxynitrite.18 These data are also
consistent with Jung and associates,10 who demonstrated
that high-dose intravenous sodium nitrite had no cytopro-
tective effect in a mouse brain IRI model, whereas the opti-
mal dose of nitrite prevented IRI. Duranski and associates19
also reported a dose-dependent tissue protective effect of1114 The Journal of Thoracic and Cardiovascular Surintravenous nitrite in heart and liver IRI models. Our data
suggest that nebulized nitrite also has a therapeutic range
associated with efficacy and absence of toxicity and that
3.0 mg of sodium nitrite could be a good therapeutic
dose, being both efficacious and safe, for nebulization to do-
nor lungs.
An important finding in our studywas that themechanism
of effect of inhaled nitrite appears to be mediated via NO.
Experiments using C-PTIO, a scavenger of NO, provide
strong data suggesting that the cytoprotective effects of ni-
trite in our model are mediated via NO-dependent pathways
after conversion of nitrite to NO, as shown in other re-
ports.10,19,20 These data are further supported by the
finding of a dose-dependent increase in lung tissue cGMP.gery c April 2013
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FIGURE 5. Cyclic guanosine monophosphate (cGMP) level in lung graft. A, There was an increase in the cGMP concentration in the lung tissue after
2 hours of reperfusion in the nitrite group compared with that in the control group (*P ¼ .04). B, The N5.0 group had higher cGMP concentrations than
the other dosage groups (*P< .001, **P< .01). C, The CPTIO1 and CPTIO2 groups had lower levels of cGMP than the nitrite group (P ¼ .051).
C-PTIO, 2-(4-carboxypheny)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide.
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onset of cold ischemia), which scavenged NO during ische-
mia and reperfusion, and the CPTIO2 group (C-PTIO deliv-
ered immediately before reperfusion), which scavenged NO
only during reperfusion, demonstrated similar results, with
significantly deteriorated pulmonary physiologic function
in both groups. It is suggested from these data that the im-
portant period for nitrite/NO efficacy for the current deliv-
ery strategy was during reperfusion, not during cold
storage, because the inhibitory action of C-PTIO in both
the CPTIO1 and CPTIO2 groups overlapped only during re-
perfusion. Regarding NO therapeutics, there is controversy
in the literature regarding the most beneficial timing of NO
administration during ischemia or during reperfusion. Sev-
eral studies support the administration of NO in early ische-
mia in lung ischemia models,21 wherreas other studies
demonstrated more cytoprotective effects of NO during re-
perfusion than during ischemia in rat small bowel and lung
ischemia models.22 Our present data using C-PTIO support
the latter findings indirectly, although we did not conduct
a direct evaluation using an additional group with the ad-
ministration of nitrite during reperfusion.
In addition to evidence of cytoprotection by inhaled NO
in rat lungs,23 much evidence suggests that several NO
donors can inhibit lung IRI, including nitroglycerin and
nitroprusside.24,25 As opposed to inhaled NO, a benefit
of nitrite is that NO generation from nitrite would
occur in tissue beds undergoing oxidative stress and at
physiologic concentrations, thus minimizing the possibility
of deleterious effects. Second, nitrite does not produceThe Journal of Thoracic and Cara tolerance phenomenon, which limits the therapeutic
efficiency of nitroglycerin.24 The third benefit is that the
measurement of nitrite concentrations in both blood and tis-
sues can be easily performed to determine the optimal
dosage and prevent toxicity, whereas NO is unstable and
can be rapidly metabolized within a few seconds, making
it difficult to determine the NO concentration in blood and
tissue in clinical situations. Therefore, nebulized sodium
nitrite may be safe and efficacious as a therapeutic agent in
clinical LTx.
In this study, we have shown that nebulized nitrite miti-
gates lung IRI in a dose-dependent manner in a rat LTx
model using standard, cold static lung storage. To expand
the donor lung supply to meet demand, there has been
much interest in the use of DCD lung donors as well as in
ex vivo perfusion for lung resuscitation. Delivery of thera-
peutic agents to lungs on ex vivo perfusion circuits has
been an area of interest of investigators and could poten-
tially be applied in the setting of DCD donors (where the
circulation has ceased) as well. Delivery of nitrite via inha-
lation in these scenarios could prove beneficial.
In conclusion, the present study demonstrates that nebu-
lized nitrite has remarkable cytoprotective effects against
IRI in a rat left LTx model. Although therapy using nebu-
lized nitrite has a limited optimal dosage range, data from
physiologic, immunologic, and molecular analyses, as
well as pharmacokinetic evaluations, were consistent with
the cytoprotective effect of sodium nitrite against lung
IRI. The inhibition of NO by C-PTIO and the dose-
dependent generation of cGMP suggests that the effects ofdiovascular Surgery c Volume 145, Number 4 1115
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Sinhaled nitrite in this model are mediated by an NO-
dependent mechanism. This approach may hold promise
for clinical translation.
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FIGUREE1. Inhibition of nitric oxide (NO) by 2-(4-carboxypheny)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (C-PTIO). A, Pulmonary vein oxygen
tension (Po2) (inspired oxygen fraction [Fio2]¼ 1.0) was analyzed after 2 hours of reperfusion using 2-(4-carboxypheny)-4,4,5,5-tetramethylimidazoline-1-
oxyl-3-oxide (C-PTIO). In the CPTIO1 group, where C-PTIO was administered in donor animals before cold ischemia, PO2 was lower than that in the nitrite
group (80.2  20.3 mm Hg vs 560.8  26.8 mm Hg; *P<.001). In the CPTIO2 group, where C-PTIO was administered in recipient animals 10 minutes
before reperfusion, PO2 was lower than that in the nitrite group (70.8  12.4 mm Hg; **P<.001). B, The peak airway pressure (PAWP) of the trachea was
measured after 2 hours of reperfusion. In the CPTIO1 group, PAWP was higher than that in the nitrite group (7.8  0.3 mm Hg vs 5.8  0.3 mm Hg;
*P ¼ .006). In the CPTIO2 group, PAWP was higher than that in the nitrite group (7.5  0.3 mm Hg vs 5.8  0.3 mm Hg; **P ¼ .01). C, The graft
wet/dry ratio was measured after 2 hours of reperfusion. Both the CPTIO1 and CPTIO2 groups had higher wet/dry ratios than the nitrite group
(P ¼ .13). PV, Pulmonary vein.
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